Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 12, 2024, by Trevi Therapeutics, Inc., a Delaware corporation. The filing addresses a significant development in the Company's clinical trial program for its product candidate, Haduvio, specifically regarding the Phase 2b CORAL trial for idiopathic pulmonary fibrosis (IPF) patients with chronic cough.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical trial progress and does not contain financial statements.
Material Changes and Clinical Update
- Sample Size Re-estimation (SSRE): The Company announced a positive outcome from the planned SSRE for the CORAL trial. The analysis determined that no change to the current sample size (N=160) is required.
- Enrollment Status: The trial has reached 75% of its targeted enrollment.
- Analysis Basis: The SSRE was conducted on the highest dose (108mg twice daily) after 80 patients (50% of initial enrollment) completed six weeks of treatment.
- Recommendation: The trial should continue as planned to maintain a pre-specified conditional power of 80% or greater, avoiding the alternative outcomes of increasing sample size or declaring futility.
Guidance, Outlook, and Risks
Outlook: Topline results from the full CORAL trial continue to be expected in the first half of 2025.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include uncertainties regarding the success, cost, and timing of product development; the possibility that positive SSRE data may not predict later clinical trial results; and regulatory uncertainties regarding the development path for Haduvio in the U.S. and foreign countries.
Key Facts for Investor Verification
- Confirm the continued enrollment rate to ensure the 75% milestone is sustained and the trial remains on track for H1 2025 results.
- Monitor subsequent filings for any updates on the regulatory strategy for Haduvio following the SSRE confirmation.
- Review the most recent Form 10-Q (for the quarter ended September 30, 2024) for current cash position and burn rate, as this 8-K does not contain financial data.
- Verify the specific endpoints and statistical methodology used in the SSRE analysis in future detailed clinical updates.